Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients
About this item
Full title
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients
Author / Creator
Publisher
England
Journal title
Journal of translational medicine, 2023-05, Vol.21 (1), p.318
Language
English
Formats
Publication information
Publisher
England
Subjects
More information
Scope and Contents
Contents
Nivolumab is an anti-PD1 antibody that has dramatically improved metastatic melanoma patients' outcomes. Nevertheless, many patients are resistant to PD-1 inhibition, occasionally experiencing severe off-target immune toxicity. In addition, no robust and reproducible biomarkers have yet been validated to identify the correct selection of patients w...
Alternative Titles
Full title
Potential clinical implications of CD4 + CD26 high T cells for nivolumab treated melanoma patients
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmed_primary_37170241
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmed_primary_37170241
Other Identifiers
E-ISSN
1479-5876
DOI
10.1186/s12967-023-04184-6
